2 recruiting, 2 unknown, 1 not yet recruiting. 4 Early Phase 1, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 4 | Recruiting 2, Unknown 2 |
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow NK510: new trials by email Literature Review of NK510 trials Research Report on NK510
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) BL-B01D1, VSV injection, CVL006 - Rare Malignant Neoplasm, Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 600 | 2026-01-01 | 2025-12-29 |
| Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer NK510 - Gastric Cancer (GC), Colorectal Cancer | Early Phase 1 | Recruiting | Base Therapeutics (Shanghai) Co., Ltd. | 15 | 2025-10-16 | 2026-10-01 |
| Safety and Efficacy of NK510 to Treat Gastric Cancer NK510, Tislelizumab，atezolizumab or Trastuzumab - Gastric Cancer | Early Phase 1 | Unknown | Base Therapeutics (Shanghai) Co., Ltd. | 9 | 2023-11-01 | 2023-10-25 |
| Safety and Efficacy of NK510 to Treat NSCLC NK510, Tislelizumab，atezolizumab or sugemalimab, systemic therapy as selected by the investigator - NSCLC | Early Phase 1 | Recruiting | Base Therapeutics (Shanghai) Co., Ltd. | 12 | 2023-07-01 | 2026-09-09 |
| Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma NK510 - Osteosarcoma, Soft Tissue Sarcoma | Early Phase 1 | Unknown | Base Therapeutics (Shanghai) Co., Ltd. | 12 | 2022-09-01 | 2023-11-07 |
Stomach Neoplasms (2) · Colorectal Neoplasms (1) · Osteosarcoma (1) · Pleural Effusion, Malignant (1) · Sarcoma (1)
Base Therapeutics (Shanghai) Co., Ltd. (4) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)
China (4)
Ning Li, MD (1) · Tangfeng Lv, PhD (1) · Yingqi Hua, phD (1)